News Releases

27 Nov '2020
Advaxis, Inc. Announces Closing of $9.2 Million Public Offering
PRINCETON, N.J. , Nov. 27, 2020 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS) (the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced the closing of an underwritten public offering of 26,666,666 shares of
PDF Version
24 Nov '2020
Advaxis, Inc. Announces Pricing of $8 Million Public Offering
PRINCETON, N.J. , Nov. 24, 2020 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS) (the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced the pricing of an underwritten public offering of (i) 26,666,666
PDF Version
29 Sep '2020
Advaxis, Inc. Adopts Limited Duration Stockholder Rights Plan
PRINCETON, N.J. , Sept. 29, 2020 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced that its Board of Directors has approved the adoption of a limited duration
PDF Version
04 Sep '2020
Advaxis Announces Resignation of Chief Financial Officer
PRINCETON, N.J. , Sept. 04, 2020 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products today announced that Molly Henderson , Executive Vice President and Chief Financial Officer, has
PDF Version
Displaying 1 - 10 of 25